Discover what is going on in the network of the LIFE Cooperative. Find here updates about members, the ecosystem en important announcements.
Medicine shortages are still increasing in the Netherlands. Doctors and pharmacists have been sounding the alarm for some time now because crucial medicines are increasingly unavailable to patients. The need for medicine production in the Netherlands is indisputable, but how do you start and strengthen this process? This issue was central during the second edition of the LIFE Sciences Conference on Tuesday, September 26, 2023, led by chairperson Rosanne Hertzberger, in a sold-out Forum Groningen. During this conference, the LIFE Cooperative, together with partners, once again brought together the players of the Life Science & Health sector in (Northern) Netherlands, this year under the theme 'Bringing Back Drug Manufacturing to the Netherlands'.
ParaMedir, an innovative medical technology company based in the Northern Netherlands, is proud to announce the significant EFRO subsidy of about €600,000.00 awarded by SNN (Samenwerkingsverband Noord-Nederland). This subsidy will support a groundbreaking consortium led by ParaMedir in their mission to improve healthcare through innovative (bio)monitoring solutions. Next to the subsidy granted by the SNN, the province of Groningen and the municipality of Groningen have both agreed to finance this project as well, contributing about €130,000.00, underlining the importance of this project for the region.
Reyedar, een deeptech startup en LIFE Cooperative lid die vroegtijdige screening van leeftijdsgerelateerde degeneratieve ziekten mogelijk maakt, kondigt vandaag aan dat het een investering van € 3 miljoen heeft binnengehaald om zijn baanbrekende oplossing verder te ontwikkelen. Reyedar ontwikkelt een eigen medisch technologieplatform op basis van eye tracking en deep learning waarmee veel symptomen van leeftijdsgerelateerde ziekten vroegtijdig kunnen worden gedetecteerd. De financieringsronde wordt geleid door Cottonwood Technology Fund, een toonaangevend durfkapitaal fonds dat investeert in technologiebedrijven in een vroeg stadium. NOM, Pupil Labs, Uneti Ventures en de reeds bestaande investeerder Blue Sparrows MedTech Fund doen ook mee in deze investeringsronde.
Today, the National Growth Fund announced that PharmaNL has met the conditions to convert the conditional allocation of €78.8 million into a definitive grant. “We at PharmaNL are delighted with this news. Together with stakeholders, we can now begin implementing the ambitions of PharmaNL,” said Brigitte Drees, Director of Pivot Park.
